We are live on ! Find out more
IMPL

Impel Pharmaceuticals Inc. Common Stock
IMPL

Delisted

IMPL was delisted on the 15th of December, 2023.

Back to rankings

33 hedge funds and large institutions have $150M invested in Impel Pharmaceuticals Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
33
Holders Change
+33
Holders Change %
–
% of All Funds
0.57%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.07%
New
33
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KKRC
Kohlberg Kravis Roberts & Co
New York
+$45.4M
2
NVPX
Norwest Venture Partners XIV
California
+$36.7M
3
5VM
5AM Venture Management
California
+$34.4M
4
VC
Vivo Capital
California
+$34.4M
5
VP
venBio Partners
California
+$33M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
KKRC
1
Kohlberg Kravis Roberts & Co
New York
$33.7M +$45.4M +3,802,639 New
NVPX
2
Norwest Venture Partners XIV
California
$27.2M +$36.7M +3,077,198 New
VC
3
Vivo Capital
California
$25.5M +$34.4M +2,884,789 New
5VM
4
5AM Venture Management
California
$25.5M +$34.4M +2,884,791 New
VP
5
venBio Partners
California
$24.4M +$33M +2,759,791 New
LM
6
Lasry Marc
$2.92M +$3.94M +330,000 New
BlackRock
7
BlackRock
New York
$2.22M +$3M +251,063 New
DKCM
8
Davidson Kempner Capital Management
New York
$2.02M +$2.75M +230,238 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.63M +$2.19M +183,753 New
WP
10
Woodline Partners
California
$1.06M +$1.43M +119,615 New
Victory Capital Management
11
Victory Capital Management
Texas
$998K +$1.35M +112,730 New
Northern Trust
12
Northern Trust
Illinois
$518K +$698K +58,493 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$450K +$608K +50,942 New
State Street
14
State Street
Massachusetts
$410K +$553K +46,298 New
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$240K +$324K +27,142 New
ZP
16
Zimmer Partners
New York
$221K +$299K +25,000 New
New York State Common Retirement Fund
17
New York State Common Retirement Fund
New York
$121K +$164K +13,700 New
Charles Schwab
18
Charles Schwab
California
$102K +$136K +11,413 New
Two Sigma Investments
19
Two Sigma Investments
New York
$89K +$120K +10,043 New
Morgan Stanley
20
Morgan Stanley
New York
$69K +$94.2K +7,888 New
California State Teachers Retirement System (CalSTRS)
21
California State Teachers Retirement System (CalSTRS)
California
$66K +$89.1K +7,464 New
JP Morgan Chase
22
JP Morgan Chase
New York
$59K +$79.4K +6,653 New
PCM
23
Pinz Capital Management
New York
$55K +$73.9K +6,188 New
Deutsche Bank
24
Deutsche Bank
Germany
$28K +$38.2K +3,196 New
UBS Group
25
UBS Group
Switzerland
$10K +$14K +1,170 New
1
2

IMPL Hedge Fund Activity: Q2 2021 in Review

33 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q2 2021, worth a combined $150M.

Buyers outnumbered sellers: 33 funds opened new IMPL positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Kohlberg Kravis Roberts & Co, opening a new position worth an estimated $45.4M.

  • 33 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $150M of Impel Pharmaceuticals Inc. Common Stock stock for Q2 2021.
  • 33 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q2 2021 and 0 closed out, a net change of +33 holders.
  • The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q2 2021 was Kohlberg Kravis Roberts & Co, an estimated $45.4M added.

Based on aggregated 13F filings for Q2 2021.